Novartis announces commencement of tender offer to acquire Regulus TherapeuticsGlobeNewsWire • 05/27/25
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesPRNewsWire • 05/08/25
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLSBusiness Wire • 05/04/25
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLSPRNewsWire • 04/30/25
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 MillionBenzinga • 04/30/25
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to ShareholdersBusiness Wire • 04/30/25
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public ShareholdersBusiness Wire • 04/30/25
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failureGlobeNewsWire • 04/30/25
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech SummitPRNewsWire • 04/02/25
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney DiseaseBenzinga • 03/27/25
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 03/27/25
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent UpdatesPRNewsWire • 03/13/25
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare ConferencePRNewsWire • 03/04/25
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferencePRNewsWire • 02/04/25
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)PRNewsWire • 01/29/25
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesPRNewsWire • 11/26/24